Chemotherapy fog targets stomach tumors in early trial

NCT ID NCT07487168

Not yet recruiting Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a technique called PIPAC, which turns a chemotherapy drug (mitomycin C) into a mist and sprays it directly onto cancer spread inside the abdomen. It is for people with advanced gastrointestinal cancers that cannot be removed by surgery. The main goal is to find a safe dose and see if it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mitomycin C (chemotherapy drug)
What this could lead to: If successful, this could offer a new palliative treatment option for patients with advanced abdominal cancer who cannot have standard surgery.
What could go wrong: This is a very early Phase 1 trial with only 24 participants, so safety and the right dose are still unknown. The cancer is advanced and incurable, so the goal is control, not cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERITONEAL CARCINOMATOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

appendiceal neoplasm colorectal neoplasm peritoneal carcinomatosis Peritoneal Diseases peritoneal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERITONEAL CARCINOMATOSIS

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.